Major Depressive Disorder (MDD) | European Drug Utilization Study
Major Depressive Disorder (MDD) research study
What is the primary objective of this study?
The purpose of this retrospective observational study is to evaluate the characteristics of patients receiving Seroquel XR as treatment for their Major Depressive Disorder. The study will also investigate how the medication is used for these patients and if there are any differences in drug utilisation between the included countries. The study is observing patients initiating Seroquel XR during a 9 month period corresponding to 3 to 12 months following the launch of the product in each country for the MDD indication. A drug utilisation questionnaire will be used to collect study data from patients' medical records.
Who is eligible to participate?
Inclusion Criteria: - Provision of informed consent before initiation of any collection of questionnaire data. - Documented clinical diagnosis of Major Depressive Disorder, Single Episode, or Recurrent. - Initiation of Seroquel XR for treatment of MDD during the period defining the inception cohort, i.e. from 3 months after launch until the index date (12 months after launch). Exclusion Criteria: - If participating in any clinical trial during the time from 3 months after launch until the index date, the patient cannot take part in this study.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Major Depressive Disorder (MDD)
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Seroquel XR group
Start Date: April 24, 2012
Completed Date: March 27, 2014
Primary Outcome: Patient age (mean and range)
Secondary Outcome: Patient referral pathway (%)
Study sponsors, principal investigator, and references
Principal Investigator: Hans A Eriksson, MD
Lead Sponsor: AstraZeneca